These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18640722)

  • 1. The effect of alternative staff time data collection methods on drug treatment service cost estimates.
    Zarkin GA; Dunlap LJ; Wedehase B; Cowell AJ
    Eval Program Plann; 2008 Nov; 31(4):427-35. PubMed ID: 18640722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unit cost of counseling and patients length of stay in a residential drug treatment setting.
    Alemi F; Haack M; Holifield L; Claudio Y; Haqqi K
    J Ment Health Policy Econ; 2002 Sep; 5(3):103-7. PubMed ID: 12728196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical review of accounting and economic methods for estimating the costs of addiction treatment.
    Cartwright WS
    J Subst Abuse Treat; 2008 Apr; 34(3):302-10. PubMed ID: 17614244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The costs of pursuing accreditation for methadone treatment sites: results from a national study.
    Zarkin GA; Dunlap LJ; Homsi G
    Eval Rev; 2006 Apr; 30(2):119-38. PubMed ID: 16492995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
    Woodward AM; Raskin IE; Blacklow B
    Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costing substance misuse services.
    Coyle D; Godfrey C; Hardman G; Raistrick D
    Addiction; 1997 Aug; 92(8):1007-15. PubMed ID: 9376770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing methadone medical maintenance in community-based clinics: disseminating evidence-based treatment.
    King VL; Burke C; Stoller KB; Neufeld KJ; Peirce J; Kolodner K; Kidorf M; Brooner RK
    J Subst Abuse Treat; 2008 Oct; 35(3):312-21. PubMed ID: 18294805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic costs of drug abuse: financial, cost of illness, and services.
    Cartwright WS
    J Subst Abuse Treat; 2008 Mar; 34(2):224-33. PubMed ID: 17596904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conceptual framework for estimating the social cost of drug abuse.
    French MT; Rachal JV; Hubbard RL
    J Health Soc Policy; 1991; 2(3):1-22. PubMed ID: 10170913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity based costing of probation with and without substance abuse treatment: a case study.
    Alemi F; Taxman F; Doyon V; Thanner M; Baghi H
    J Ment Health Policy Econ; 2004 Jun; 7(2):51-7. PubMed ID: 15208465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic evaluation of inpatient residential treatment programs in the Department of Veterans Affairs.
    Wagner TH; Chen S
    Med Care Res Rev; 2005 Apr; 62(2):187-204. PubMed ID: 15750176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a low-cost incentive intervention to improve counseling attendance among methadone-maintained patients.
    Sigmon SC; Stitzer ML
    J Subst Abuse Treat; 2005 Dec; 29(4):253-8. PubMed ID: 16311177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States.
    Strauss SM; Astone JM; Jarlais DD; Hagan H
    Drug Alcohol Depend; 2004 Mar; 73(3):227-36. PubMed ID: 15036545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of statistical models to predict mental health and substance abuse cost.
    Montez-Rath M; Christiansen CL; Ettner SL; Loveland S; Rosen AK
    BMC Med Res Methodol; 2006 Oct; 6():53. PubMed ID: 17067394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and benefits of combining probation and substance abuse treatment.
    Alemi F; Taxman F; Baghi H; Vang J; Thanner M; Doyon V
    J Ment Health Policy Econ; 2006 Jun; 9(2):57-70. PubMed ID: 17007484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP).
    French MT; Dunlap LJ; Zarkin GA; McGeary KA; McLellan AT
    J Subst Abuse Treat; 1997; 14(5):445-55. PubMed ID: 9437614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost estimation when time and resources are limited: the Brief DATCAP.
    French MT; Roebuck MC; McLellan AT
    J Subst Abuse Treat; 2004 Oct; 27(3):187-93. PubMed ID: 15501371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.